1. Home /
  2. Real Money Pro

Real Money Pro

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

Greenbrier's Dividend Entices, but Could Be Derailed by a Tough Economy

The rail car maker is likely riding into a slower period of demand for its products, which investors should keep in mind when considering it as a dividend play.

How to Use a Buy-Write Options Strategy With Out-Of-Favor ETFs

Financials and energy ETFs aren't faring well in the current environment, but there still is a way to make money on them.

Caution Is the Watchword of the Day in Investing

It's hard to put much stock in achieving real progress on trade talks with China, and with the yield curve inverting and global economies sagging it's time to be on guard in the markets.

Are We Heading for a Recession? Let's Check Out Oil and Copper for Clues

The two commodities are in downtrends, which when combined with an economic expansion that is long in the tooth could indicate a recession is on the horizon.

This Furniture Retailer Furnishes Its Owners With a Nice Yield

Haverty Furniture Cos., aka Havertys, has paid a cash dividend every year for more than eight decades and occasionally surprises shareholders with a special payout.

Checking In on 2 Small Biotech Names That Had Big Quarters

Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.

3 Tariff Questions That Must Wait for Answers

It will take time to determine the impact of new tariffs on consumer prices, business bottom lines and the achievement of a trade deal with China.

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts

Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.